Effects of PTEN loss and activated KRAS overexpression on mechanical properties of breast epithelial cells
JournalInternational Journal of Molecular Sciences
MetadataShow full item record
AbstractIt has previously been shown that the simultaneous activation of PI3K (phosphatidylinositol 3-kinase) and Ras/MAPK (mitogen-activated protein kinases) pathways facilitate tumor growth despite only inducing cancer cell dormancy individually. Determining the impacts on cellular mechanics each pathway incites alone and in unison is critical to developing non-toxic cancer therapies for triple-negative breast cancers. PTEN (phosphatase and tensin homolog) knockout and activated KRAS (Kristen rat sarcoma viral oncogene homolog) overexpression in healthy MCF-10A human breast epithelial cells activated the PI3K and Ras/MAPK pathways, respectively. Cell stiffness and fluidity were simultaneously measured using atomic force microscopy. Results suggest that PTEN knockout reduced cell stiffness and increased cell fluidity independent of PI3K activation. Effects of activated KRAS overexpression on cell stiffness depends on rigidity of cell culture substrate. Activated KRAS overexpression also counteracts the effects of PTEN knockout. Copyright 2018 by the authors. Licensee MDPI, Basel, Switzerland.
SponsorsAcknowledgments: This research is supported by NSF grant CBET-1403257 (Q.W.), IGERT-DGE-1144804 (W.L.), NIH grant K01-CA166576 (M.I.V.), and 122229-IRG-97-153-10-IRG from the American Cancer Society (M.I.V.).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85047907998&doi=10.3390%2fijms19061613&partnerID=40&md5=95ad1e5b9a644e9b01558d5140d006c5; http://hdl.handle.net/10713/8938
- PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
- Authors: Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL
- Issue date: 2009 Mar
- The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence.
- Authors: Thompson KN, Whipple RA, Yoon JR, Lipsky M, Charpentier MS, Boggs AE, Chakrabarti KR, Bhandary L, Hessler LK, Martin SS, Vitolo MI
- Issue date: 2015 Nov 3
- Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
- Authors: Yuen HF, Chan KK, Grills C, Murray JT, Platt-Higgins A, Eldin OS, O'Byrne K, Janne P, Fennell DA, Johnston PG, Rudland PS, El-Tanani M
- Issue date: 2012 Jan 15
- Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
- Authors: Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R
- Issue date: 2014 Sep 11
- Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
- Authors: Yip WK, Choo CW, Leong VC, Leong PP, Jabar MF, Seow HF
- Issue date: 2013 Oct